Akademik Veri Yönetim Sistemi
Medical Bulletin of Istanbul Medical Faculty, cilt.28, sa.2, ss.1-9, 1995 (Scopus)
The aim of this study was to compare the efficacy and tolerability of benazepril and captopril in patients with mild to moderate essential hypertension. This was a multicenter, randomized double-blind trial for 8 weeks. After a wash-out period of 2 weeks for the patients previously on hypertensive agents, 70 patients (40 females, 30 males; the mean age was 49 8 years) were randomly allocated to benazepril (CIBACEN) 10 mg once daily (od) or captopril 25 mg twice daily (bid). There were 35 patients (19 women and 16 men; the mean age was 48 8 years) in benazepril group and 35 patients (21 females and 14 males the mean age was 50 9 years) in captopril group. If the target value of supine diastolic blood pressure (BP) (| 90 mmHg) could not be achieved, the doses of both drugs were doubled after 2 weeks. Two weeks later in patients with uncontrolled diastolic BP, hydrochlorothiazid (12.5 mg od) was added to the treatment. If diastolic BP was still not controlled after 2 weeks, the dose of hydrochlorothiazid was increased to 25 mg once daily. The mean values of systolic and diastolic BP's both supine and standing positions were significantly reduced 2 weeks after initiation of therapy on both benazepril group (p<0.001, p<0.001, p<0.001 and p<0.001) and captopril group (p<0.001, p<0.001, p<0.001 and p<0.001). At the end of the trial, diastolic BP on supine position reduced below 90 mm Hg in 88% of patients in benazepril group and in 86% of patients in captopril group. We did not observe any significant difference in the mean values of parameters of blood analysis, haemogram and ECG after therapy on both groups. There were mild and reversible side effects in 6 patients (17%) in benazepril group and in 8 patients (23%) in captopril group. Drug was discontinued in 1 patient (3%) due to cough on benazepril treatment. We conclude that benazepril once a day and captopril twice a day are equally effective and safe drugs in the treatment of patients with mild to moderate essential hypertension.